The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This is a prospective, non-interventional study of adult patients prescribed topical
treatment with ingenol mebutate gel (Picato®) as part of provision of care for the treatment
of Non-hyperkeratotic, non-hypertrophic Actinic Keratosis (AK). Patients with complete
clearance at 8 weeks will be followed for one year or until retreatment of AK in the area
initially treated, whatever comes first. For patients with incomplete clearance in the
treated area at 8 weeks the treatment strategy for this area will be recorded but no further
follow-up will take place. The effectiveness, tolerability, adherence, patient satisfaction
and health-related quality of life (HRQoL) associated with Picato® treatment will be
evaluated.